Bumetanide

Seizures

Soul, Janet , M.D.Small moleculePhase 1Dormant

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 89/ 100

Competitive context

77 Active assets in the Seizures cohort.

Asset / Sponsor	Phase	Rating
Topamax SK Life Science, Inc.	Phase 4	BBB
Keppra Beijing Tiantan Hospital	Phase 4	BBB
Topamax Université de Sherbrooke	Phase 4	BBB
Lacosamide Second Affiliated Hospital of Guangzhou Medical University	Phase 4	BBB
Eslicarbazepine Acetate Bial - Portela C S.A.	Phase 4	BBB

View all 50 →

Same molecule, other indications

Bumetanide is also rated in:

cirrhosis of liverDormant

CCC

Indicative ·

54 / 100

Parkinson diseaseDormant

CCC

Indicative ·

48 / 100

Alzheimer diseaseDormant

CCC

Indicative ·

48 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.